Anti-Migraine Therapies 2005 -- B2B Conferences (visiongain)

Attend the visiongains b2b conference, ANTI-MIGRAINE THERAPIES 2005: IMPROVING DISEASE UNDERSTANDING, DRUG DELIVERY AND FUTURE TARGETS. This conferences objective is to provide a unique forum to discuss the new developments in significant areas of the anti-migraine therapies market. This includes new research data to innovations in drug delivery to future targets for drugs.

London, UK (PRWEB) November 28, 2004 -- Attend the visiongains b2b conference, ANTI-MIGRAINE THERAPIES 2005: IMPROVING DISEASE UNDERSTANDING, DRUG DELIVERY AND FUTURE TARGETS. This conferences objective is to provide a unique forum to discuss the new developments in significant areas of the anti-migraine therapies market. This includes new research data to innovations in drug delivery to future targets for drugs.

Migraine is the most common neurological condition in the developed world. In the seven major pharmaceutical markets, (US, France, Germany, Italy, Spain, UK and Japan) migraine afflicted more than 74 million people in 2002. It affects 11% of the UK population and is more prevalent than diabetes, epilepsy and asthma combined.

Over the two days, this event will provide a comprehensive focus on the potential for genetic research in the future of migraine treatments and discovery the possibilities for new drugs. Leaders from the Pharmaceutical sector will also investigate the main challenges involved in alternative therapies and the new possibilities for Botox as an anti-migraine treatment. Learn directly from the experts: focused and detailed case studies from industry leaders GSK, Boehringer-Ingelheim; Aradigm. Additional, discover the possible future targets for anti-migraine therapies and learn which are the areas to watch: ensure your company gains its share of the market and the benefit from the new treatment technology available and achieve more efficient drug delivery for your drugs

The ANTI-MIGRAINE THERAPIES CONFERENCE will take place on March 8th & 9th at the Hilton Kensington Hotel, London.

Companies and organisations participating in the conference program:
- Dr. Michael James, Head of Preclinical MRI, Neurology & Gastrointestinal CEDD , GlaxoSmithKline
- Dr. Henry Doods, Head of Pain Research, Boehringer-Ingelheim
- Dr. Stephen Farr, Chief Scientific Officer, Aradigm
- Dr. Chas Bountra, Head, Pain Research, GlaxoSmithKline
- Barry Cohen, Vice President & New Product Development, NovaDel
- Dr. Stephen Silberstein, Director, Jefferson Headache Center
- Dr. Don Penzien, Director & Founder, UMC Head Pain Center
- Dr. Ann Pakalnis, Clinical Associate Professor of Paediatrics & Neurology, Ohio State University & Columbus Childrens Hospital

Complementing this conference, is a Pre-conference Interactive Workshop (Thursday 7th March 2005) entitled PRICING AND POSITIONING FOR AN INNOVATIVE ANTI-MIGRAINE TREATMENT which will be led by:

Mr. Christian Schuler, Director, Health Sciences Division, Simon-Kucher & Partners

This pre-conference workshop focuses on pricing and reimbursement environment in the anti-migraine market    and value based pricing for a new anti-migraine treatment. With an in-depth analysis of the ideal positioning of an innovative anti-migraine therapy and how to derive optimal prices.

For more information about this event, please visit www.b2b-conferences.com

About B2B Conferences:
B2B Conferences is one of Europes fastest growing media companies today, basing its knowledge on the raft of management reports and industry news letter that the parent company produces each year. B2B Conferences has built up a solid reputation for putting together high quality business to business event workshops aimed at the corporate community.

These events are unique in that B2B operates on a wholly independent basis, therefore producing conferences that are timely, targeted and at time controversial, giving delegates, speakers and sponsors alike, the opportunity to get a totally unbiased view of their industry.

For additional information contact:
Senh Ip
Corporate communications
Tel: +44 (0) 20 8767 6711
Fax: +44 (0) 20 8767 5001
Email: Senh.ip@visiongain.com

For more information visiongain, please visit www.visiongain.com

# # #

Corporate tables and sponsorship/exhibitor opportunities are still available; please call the hotline or email Andrew.oliver@visiongain.com for more information.